Insmed Reports 44% Sequential Growth for Brinsupri, Reaffirms 2026 Revenue Target
Thursday / 21-05-2026, 20:40 WIB
Insmed Incorporated announced 44% sequential growth for its oral drug Brinsupri in Q1 2026. The company reaffirms its 2026 revenue outlook of at least $1 billion, driven by stable pricing and patient acquisition.